Product Description: NG-nitro-L-arginine (Nω-nitro-L-arginine) is a NO Synthase inhibitor, with Kis of 0.61 μM (nNOS), 4.28 μM (iNOS), 0.72 μM (eNOS) respectively. NG-nitro-L-arginine inhibits endothelium-derived relaxing factor (EDRF) formation and release. NG-nitro-L-arginine inhibits portal-systemic shunting in portal-hypertensive rats, and increases blood pressure[1][2][3][4].
Formula: C6H13N5O4
References: [1]Seo J, et al. Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. J Med Chem. 2007 May 3;50(9):2089-99. /[2]Ishii K, et al. N omega-nitro-L-arginine: a potent inhibitor of endothelium-derived relaxing factor formation. Eur J Pharmacol. 1990 Feb 6;176(2):219-23. /[3]Lee FY, et al. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology. 1993 Nov;105(5):1464-70./[4]Molnár M, Hertelendy F. N omega-nitro-L-arginine, an inhibitor of nitric oxide synthesis, increases blood pressure in rats and reverses the pregnancy-induced refractoriness to vasopressor agents. Am J Obstet Gynecol. 1992 May;166(5):1560-7.
CAS Number: 2149-70-4
Molecular Weight: 219.20
Compound Purity: 99.78
Research Area: Cardiovascular Disease
Target: NO Synthase
Deutsch
English
